Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 handwiki Rita Xu -- 3215 2022-10-21 01:34:01

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
HandWiki. Progestin. Encyclopedia. Available online: https://encyclopedia.pub/entry/30637 (accessed on 21 October 2026).
HandWiki. Progestin. Encyclopedia. Available at: https://encyclopedia.pub/entry/30637. Accessed October 21, 2026.
HandWiki. "Progestin" Encyclopedia, https://encyclopedia.pub/entry/30637 (accessed October 21, 2026).
HandWiki. (2022, October 21). Progestin. In Encyclopedia. https://encyclopedia.pub/entry/30637
HandWiki. "Progestin." Encyclopedia. Web. 21 October, 2022.

Progestin

Edit
The content is sourced from: https://handwiki.org/wiki/Chemistry:Progestin

A progestin is a type of medication which is used most commonly in hormonal birth control and menopausal hormone therapy. They can also be used in the treatment of gynecological conditions, to support fertility and pregnancy, to lower sex hormone levels for various purposes, and for other indications. Progestins are used alone or in combination with estrogens. They are available in a wide variety of formulations and for use by many different routes of administration. Side effects of progestins include menstrual irregularities, headaches, nausea, breast tenderness, mood changes, acne, increased hair growth, and changes in liver protein production among others. Other side effects of progestins include an increased risk of breast cancer, cardiovascular disease, and blood clots. At high dosages, progestins can cause low sex hormone levels and associated side effects like sexual dysfunction and an increased risk of bone fractures. Progestins are synthetic progestogens and have similar effects to those of the natural hormone progesterone. They act as agonists of the progesterone receptor, and have important effects in the female reproductive system (uterus, cervix, and vagina), the breasts, and the brain. In addition, many progestins also have other hormonal activities, such as androgenic, antiandrogenic, estrogenic, glucocorticoid, or antimineralocorticoid activity. They also have antigonadotropic effects and at sufficiently high dosages can strongly suppress sex hormone production. Progestins mediate their contraceptive effects both by inhibiting ovulation and by thickening cervical mucus, thereby preventing fertilization. They have functional antiestrogenic effects in certain tissues like the endometrium, and this underlies their use in menopausal hormone therapy. Progestins were first introduced for medical use in 1939. They started to be used in birth control in the 1950s. Around 60 progestins have been marketed for clinical use in humans or use in veterinary medicine. These progestins can be grouped into different classes and generations. Progestins are available widely throughout the world and are used in all forms of hormonal birth control and in most menopausal hormone therapy regimens.

glucocorticoid menopausal ovulation

References

  1. J. Larry Jameson; Leslie J. De Groot (25 February 2015). Endocrinology: Adult and Pediatric E-Book. Elsevier Health Sciences. pp. 2304–. ISBN 978-0-323-32195-2. https://books.google.com/books?id=xmLeBgAAQBAJ&pg=PA2304. 
  2. Michelle A. Clark; Richard A. Harvey; Richard Finkel; Jose A. Rey; Karen Whalen (15 December 2011). Pharmacology. Lippincott Williams & Wilkins. p. 322. ISBN 978-1-4511-1314-3. https://books.google.com/books?id=Y558dgp_PjoC&pg=PA322. 
  3. Bhattacharya (1 January 2003). Pharmacology, 2/e. Elsevier India. p. 378. ISBN 978-81-8147-009-6. https://books.google.com/books?id=X3cCZQCrrjcC&pg=PA378. 
  4. Rick D. Kellerman; Edward T. Bope (10 November 2017). Conn's Current Therapy 2018 E-Book. Elsevier Health Sciences. pp. 1124–. ISBN 978-0-323-52961-7. https://books.google.com/books?id=3xNBDwAAQBAJ&pg=PT1124. 
  5. Helen Varney; Jan M. Kriebs; Carolyn L. Gegor (2004). Varney's Midwifery. Jones & Bartlett Learning. pp. 513–. ISBN 978-0-7637-1856-5. https://books.google.com/books?id=c5dn3yh4V5UC&pg=PA513. 
  6. David E. Golan (2008). Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Lippincott Williams & Wilkins. pp. 520–521. ISBN 978-0-7817-8355-2. https://books.google.com/books?id=az8uSDkB0mgC&pg=PA520. 
  7. Pamela S. Miles; William F. Rayburn; J.Christopher Carey (6 December 2012). Obstetrics and Gynecology. Springer Science & Business Media. pp. 109–. ISBN 978-1-4684-0220-9. https://books.google.com/books?id=tKigBwAAQBAJ&pg=PA109. 
  8. "Role of progestins in contraception". Acta Obstet Gynecol Scand 84 (3): 207–16. March 2005. doi:10.1111/j.0001-6349.2005.00759.x. PMID 15715527.  https://dx.doi.org/10.1111%2Fj.0001-6349.2005.00759.x
  9. "Clinical trials in male hormonal contraception". Contraception 82 (5): 457–70. 2010. doi:10.1016/j.contraception.2010.03.020. PMID 20933120. http://www.kup.at/kup/pdf/10172.pdf. 
  10. "Estrogenic side effects of androgen deprivation therapy". Rev Urol 9 (4): 163–80. 2007. PMID 18231613.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2213888
  11. "Managing hot flushes in men after prostate cancer--a systematic review". Maturitas 65 (1): 15–22. 2010. doi:10.1016/j.maturitas.2009.10.017. PMID 19962840.  https://dx.doi.org/10.1016%2Fj.maturitas.2009.10.017
  12. "Chlormadinone acetate is effective for hot flush during androgen deprivation therapy". Prostate Int 1 (3): 113–6. 2013. doi:10.12954/PI.12010. PMID 24223412.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3814123
  13. "A functional model for progestogen-induced breakthrough bleeding". Hum. Reprod. 15 Suppl 3: 1–6. August 2000. doi:10.1093/humrep/15.suppl_3.1. PMID 11041215.  https://dx.doi.org/10.1093%2Fhumrep%2F15.suppl_3.1
  14. "Dydrogesterone and other progestins in benign breast disease: an overview". Arch. Gynecol. Obstet. 283 (2): 369–71. February 2011. doi:10.1007/s00404-010-1456-7. PMID 20383772.  https://dx.doi.org/10.1007%2Fs00404-010-1456-7
  15. "Cyclic progestin therapy for the management of mastopathy and mastodynia". Gynecol. Endocrinol. 15 Suppl 6: 37–43. December 2001. PMID 12227885.  http://www.ncbi.nlm.nih.gov/pubmed/12227885
  16. "Systemic progesterone therapy--oral, vaginal, injections and even transdermal?". Maturitas 79 (3): 248–55. 2014. doi:10.1016/j.maturitas.2014.07.009. PMID 25113944.  https://dx.doi.org/10.1016%2Fj.maturitas.2014.07.009
  17. Bińkowska, Małgorzata; Woroń, Jarosław (2015). "Progestogens in menopausal hormone therapy". Menopausal Review 2: 134–143. doi:10.5114/pm.2015.52154. ISSN 1643-8876.  https://dx.doi.org/10.5114%2Fpm.2015.52154
  18. 3.0.co;2-m. PMID 14409476.  https://dx.doi.org/10.1002%2F1097-0142%28195911%2F12%2912%3A6%3C1106%3A%3Aaid-cncr2820120607%3E3.0.co%3B2-m" id="ref_18">"Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium". Cancer 12: 1106–22. 1959. doi:10.1002/1097-0142(195911/12)12:6<1106::aid-cncr2820120607>3.0.co;2-m. PMID 14409476.  https://dx.doi.org/10.1002%2F1097-0142%28195911%2F12%2912%3A6%3C1106%3A%3Aaid-cncr2820120607%3E3.0.co%3B2-m
  19. Regulatory Mechanisms in Transcriptional Signaling. Academic Press. 25 July 2009. pp. 62–. ISBN 978-0-08-091198-4. https://books.google.com/books?id=yIESHM-P-ZIC&pg=PA62. 
  20. Loren K. Mell, MD (20 December 2011). Gynecologic Cancer. Demos Medical Publishing. pp. 393–. ISBN 978-1-61705-095-4. https://books.google.com/books?id=K0CaWNG4L6sC&pg=PA393. 
  21. Robert G. McKinnell (13 March 1998). The Biological Basis of Cancer. Cambridge University Press. pp. 262–. ISBN 978-0-521-59695-4. https://books.google.com/books?id=7DPzBK27R_EC&pg=PA262. 
  22. Jacqueline Burchum; Laura Rosenthal (2 December 2014). Lehne's Pharmacology for Nursing Care - E-Book. Elsevier Health Sciences. pp. 740–. ISBN 978-0-323-34026-7. https://books.google.com/books?id=C7_NBQAAQBAJ&pg=PA740. 
  23. H. John Smith; Hywel Williams (10 October 2005). Smith and Williams' Introduction to the Principles of Drug Design and Action, Fourth Edition. CRC Press. pp. 493–. ISBN 978-0-203-30415-0. https://books.google.com/books?id=P2W6B9FQRKsC&pg=PA493. 
  24. David J. Winchester (2006). Breast Cancer. PMPH-USA. pp. 333–. ISBN 978-1-55009-272-1. https://books.google.com/books?id=aHetwn61JigC&pg=PA333. 
  25. "Endocrine therapy for gynecological cancer". Gynecol. Endocrinol. 13 (6): 441–56. December 1999. doi:10.3109/09513599909167590. PMID 10685337.  https://dx.doi.org/10.3109%2F09513599909167590
  26. Loose, Davis S.; Stancel, George M. (2006). "Estrogens and Progestins". Goodman & Gilman's The Pharmacological Basis of Therapeutics (11th ed.). New York: McGraw-Hill. pp. 1541–71. ISBN 0-07-142280-3. 
  27. "[The antigonadrotropic activity of chlormadinone acetate in reproductive women"] (in French). Gynécologie, Obstétrique & Fertilité 33 (1-2): 29–34. 2005. doi:10.1016/j.gyobfe.2004.12.002. PMID 15752663. http://linkinghub.elsevier.com/retrieve/pii/S1297-9589(04)00378-9. 
  28. Andrea R. Genazzani (15 January 1993). Frontiers in Gynecologic and Obstetric Investigation. Taylor & Francis. p. 320. ISBN 978-1-85070-486-7. https://books.google.com/books?id=vNZ8Xb8lDF4C&pg=PA320. Retrieved 29 May 2012. 
  29. Neumann F (1978). "The physiological action of progesterone and the pharmacological effects of progestogens--a short review". Postgraduate Medical Journal 54 Suppl 2: 11–24. PMID 368741.  http://www.ncbi.nlm.nih.gov/pubmed/368741
  30. "Secondary hormonal therapy for advanced prostate cancer". J. Urol. 175 (1): 27–34. January 2006. doi:10.1016/S0022-5347(05)00034-0. PMID 16406864.  https://dx.doi.org/10.1016%2FS0022-5347%2805%2900034-0
  31. "Androgen deprivation for prostatic carcinoma: a rationale for choosing components". Int. J. Urol. 5 (4): 303–11. July 1998. doi:10.1111/j.1442-2042.1998.tb00356.x. PMID 9712436.  https://dx.doi.org/10.1111%2Fj.1442-2042.1998.tb00356.x
  32. "High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials". Ann. Oncol. 12 (3): 289–300. March 2001. doi:10.1023/a:1011156811739. PMID 11332139.  https://dx.doi.org/10.1023%2Fa%3A1011156811739
  33. "Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisal". J Chemother 15 (3): 220–5. June 2003. doi:10.1179/joc.2003.15.3.220. PMID 12868546.  https://dx.doi.org/10.1179%2Fjoc.2003.15.3.220
  34. "Clinical use of oestrogens and progestogens". Maturitas 12 (3): 199–214. September 1990. doi:10.1016/0378-5122(90)90004-P. PMID 2215269.  https://dx.doi.org/10.1016%2F0378-5122%2890%2990004-P
  35. "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric 8 Suppl 1: 3–63. 2005. doi:10.1080/13697130500148875. PMID 16112947. http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf. 
  36. "Progestogen therapies: differences in clinical effects?". Trends Endocrinol. Metab. 15 (6): 277–85. 2004. doi:10.1016/j.tem.2004.06.006. PMID 15358281.  https://dx.doi.org/10.1016%2Fj.tem.2004.06.006
  37. "Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception". Steroids 76 (7): 636–52. June 2011. doi:10.1016/j.steroids.2011.03.001. PMID 21414337.  https://dx.doi.org/10.1016%2Fj.steroids.2011.03.001
  38. "The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias". World J. Biol. Psychiatry 11 (4): 604–55. 2010. doi:10.3109/15622971003671628. PMID 20459370.  https://dx.doi.org/10.3109%2F15622971003671628
  39. Worly, Brett L.; Gur, Tamar L.; Schaffir, Jonathan (2018). "The relationship between progestin hormonal contraception and depression: a systematic review". Contraception. doi:10.1016/j.contraception.2018.01.010. ISSN 00107824.  https://dx.doi.org/10.1016%2Fj.contraception.2018.01.010
  40. "Association of Hormonal Contraception With Depression". JAMA Psychiatry 73 (11): 1154–1162. November 2016. doi:10.1001/jamapsychiatry.2016.2387. PMID 27680324.  https://dx.doi.org/10.1001%2Fjamapsychiatry.2016.2387
  41. "Progesterone receptors, their isoforms and progesterone regulated transcription". Mol. Cell. Endocrinol. 357 (1-2): 18–29. 2012. doi:10.1016/j.mce.2011.09.016. PMID 21952082.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3272316
  42. "Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression". Nucl Recept Signal 7: e009. 2009. doi:10.1621/nrs.07009. PMID 20087430.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2807635
  43. "Membrane progesterone receptors: evidence for neuroprotective, neurosteroid signaling and neuroendocrine functions in neuronal cells". Neuroendocrinology 96 (2): 162–71. 2012. doi:10.1159/000339822. PMID 22687885.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3489003
  44. "Novel progesterone receptors: neural localization and possible functions". Frontiers in Neuroscience 7: 164. 2013. doi:10.3389/fnins.2013.00164. PMID 24065878.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3776953
  45. Glasier, Anna (March 20, 2015). "Chapter 134. Contraception". in Jameson, J. Larry; De Groot, Leslie J.; de Krester, David et al.. Endocrinology: Adult and Pediatric (7th ed.). Philadelphia: Saunders Elsevier. p. 2306. ISBN 978-0-323-18907-1. 
  46. "Chapter 33. Contraception including contraception in HIV infection and infection reduction". Oxford Handbook of Genitourinary Medicine, HIV, and Sexual Health (2nd ed.). Oxford: Oxford University Press. November 19, 2010. p. 360. ISBN 978-0-19-957166-6. https://books.google.com/books?id=sTWXAwAAQBAJ&pg=PA353. "Ovulation may be suppressed in 15–40% of cycles by POPs containg levonorgestrel, norethisterone, or etynodiol diacetate, but in 97–99% by those containing desogestrel." 
  47. "Progesterone, progestins and the breast in menopause treatment". Climacteric 21 (4): 326–332. August 2018. doi:10.1080/13697137.2018.1476483. PMID 29852797.  https://dx.doi.org/10.1080%2F13697137.2018.1476483
  48. "Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone". Oncotarget 8 (47): 83334–83342. 2017. doi:10.18632/oncotarget.19833. PMID 29137347.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5669973
  49. "Pharmacodynamics of oestrogens and progestogens". Cephalalgia : an International Journal of Headache 20 (3): 200–7. April 2000. doi:10.1046/j.1468-2982.2000.00042.x. PMID 10997774. http://cep.sagepub.com/cgi/pmidlookup?view=long&pmid=10997774. 
  50. "Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male". Clinical Endocrinology 58 (4): 506–12. April 2003. doi:10.1046/j.1365-2265.2003.01751.x. PMID 12641635. http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0300-0664&date=2003&volume=58&issue=4&spage=506. 
  51. Wein, Alan J.; Kavoussi, Louis R.; Novick, Andrew C.; Partin, Alan W.; Peters, Craig A. (25 August 2011). Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set. Elsevier Health Sciences. pp. 2938–. ISBN 978-1-4160-6911-9. https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2938. 
  52. "Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men". Clinical Endocrinology 11 (5): 497–504. 1979. doi:10.1111/j.1365-2265.1979.tb03102.x. PMID 519881.  https://dx.doi.org/10.1111%2Fj.1365-2265.1979.tb03102.x
  53. Urotext (1 January 2001). Urotext-Luts: Urology. Urotext. pp. 71–. ISBN 978-1-903737-03-3. https://books.google.com/books?id=6zjtA37qDsMC&pg=PA71. 
  54. "Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial". Br J Urol 52 (3): 208–15. 1980. doi:10.1111/j.1464-410x.1980.tb02961.x. PMID 7000222.  https://dx.doi.org/10.1111%2Fj.1464-410x.1980.tb02961.x
  55. J. Horsky; J. Presl (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 329–. ISBN 978-94-009-8195-9. https://books.google.com/books?id=7IrpCAAAQBAJ&pg=PA329. 
  56. Bullock, Leslie P.; Bardin, C. W. (1977). "Androgenic, Synandrogenic, and Antiandrogenic Actions of Progestins". Annals of the New York Academy of Sciences 286 (1 Biochemical A): 321–330. doi:10.1111/j.1749-6632.1977.tb29427.x. ISSN 0077-8923. Bibcode: 1977NYASA.286..321B.  https://dx.doi.org/10.1111%2Fj.1749-6632.1977.tb29427.x
  57. Darney, Philip D. (1995). "The androgenicity of progestins". The American Journal of Medicine 98 (1): S104–S110. doi:10.1016/S0002-9343(99)80067-9. ISSN 0002-9343.  https://dx.doi.org/10.1016%2FS0002-9343%2899%2980067-9
  58. Campagnoli, Carlo; Clavel-Chapelon, Françoise; Kaaks, Rudolf; Peris, Clementina; Berrino, Franco (2005). "Progestins and progesterone in hormone replacement therapy and the risk of breast cancer". The Journal of Steroid Biochemistry and Molecular Biology 96 (2): 95–108. doi:10.1016/j.jsbmb.2005.02.014. ISSN 0960-0760. PMID 15908197.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1974841
  59. Kenneth Hugdahl; René Westerhausen (2010). The Two Halves of the Brain: Information Processing in the Cerebral Hemispheres. MIT Press. pp. 272–. ISBN 978-0-262-01413-7. https://books.google.com/books?id=v0RsKYmpe0UC&pg=PA272. 
  60. Schindler, Adolf E; Campagnoli, Carlo; Druckmann, René; Huber, Johannes; Pasqualini, Jorge R; Schweppe, Karl W; Thijssen, Jos H.H (2003). "Classification and pharmacology of progestins". Maturitas 46: 7–16. doi:10.1016/j.maturitas.2003.09.014. ISSN 0378-5122. PMID 14670641.  https://dx.doi.org/10.1016%2Fj.maturitas.2003.09.014
  61. David A. Williams; William O. Foye; Thomas L. Lemke (January 2002). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 700–. ISBN 978-0-683-30737-5. https://books.google.com/books?id=qLJ6Bs1Qml4C&pg=PA700. 
  62. Ricardo Azziz (8 November 2007). Androgen Excess Disorders in Women. Springer Science & Business Media. pp. 124–. ISBN 978-1-59745-179-6. https://books.google.com/books?id=Ch-BsGAOtucC&pg=PA124. 
  63. P. J. Bentley (1980). Endocrine Pharmacology: Physiological Basis and Therapeutic Applications. CUP Archive. pp. 4–. ISBN 978-0-521-22673-8. https://books.google.com/books?id=W6M9AAAAIAAJ&pg=PA4. 
  64. Sengupta (1 January 2007). Gynaecology For Postgraduate And Practitioners. Elsevier India. pp. 137–. ISBN 978-81-312-0436-8. https://books.google.com/books?id=ELkWa34eBz4C&pg=PA137. 
  65. Ferin, J. (1962). "Artificial Induction of Hypoestrogenic Amenorrhea with Methylestrenolone, or with Lynestrenol". European Journal of Endocrinology 39 (1): 47–67. doi:10.1530/acta.0.0390047. ISSN 0804-4643.  https://dx.doi.org/10.1530%2Facta.0.0390047
  66. Saunders, Francis J.; Drill, Victor A. (1956). "The Myotrophic and Androgenic Effects of 17-Ethyl-19-nortestosterone and Related Compounds". Endocrinology 58 (5): 567–572. doi:10.1210/endo-58-5-567. ISSN 0013-7227. PMID 13317831.  https://dx.doi.org/10.1210%2Fendo-58-5-567
  67. Christian Lauritzen; John W. W. Studd (22 June 2005). Current Management of the Menopause. CRC Press. p. 45. ISBN 978-0-203-48612-2. https://books.google.com/books?id=WD7S7677xUUC&pg=PA45. "Ethisterone, the first orally effective progestagen, was synthesized by Inhoffen and Hohlweg in 1938. Norethisterone, a progestogen still used worldwide, was synthesized by Djerassi in 1951. But this progestogen was not used immediately and in 1953 Colton discovered norethynodrel, used by Pincus in the first oral contraceptive. Numerous other progestogens were subsequently synthesized, e.g., lynestrenol and ethynodiol diacetate, which were, in fact, prhormones converted in vivo to norethisterone. All these progestogens were also able to induce androgenic effects when high doses were used. More potent progestogens were synthesized in the 1960s, e.g. norgestrel, norgestrienone. These progestogens were also more androgenic." 
  68. Armen H. Tashjian; Ehrin J. Armstrong (21 July 2011). Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Lippincott Williams & Wilkins. pp. 523–. ISBN 978-1-4511-1805-6. https://books.google.com/books?id=kjCCMZHInigC&pg=PA523. 
  69. de Gooyer, Marcel E; Deckers, Godefrides H; Schoonen, Willem G.E.J; Verheul, Herman A.M; Kloosterboer, Helenius J (2003). "Receptor profiling and endocrine interactions of tibolone". Steroids 68 (1): 21–30. doi:10.1016/S0039-128X(02)00112-5. ISSN 0039-128X. PMID 12475720. "[Norethisterone] has similar and [norethynodrel] weaker androgenic effects compared to tibolone.".  https://dx.doi.org/10.1016%2FS0039-128X%2802%2900112-5
  70. "The design and use of sex-steroid antagonists". J. Steroid Biochem. 25 (5B): 811–33. 1986. PMID 3543501. "Similar androgenic potential is inherent to norethisterone and its prodrugs (norethisterone acetate, ethynodiol diacetate, lynestrenol, norethynodrel, quingestanol).".  http://www.ncbi.nlm.nih.gov/pubmed/3543501
  71. Chaudhuri (1 January 2007). Practice Of Fertility Control: A Comprehensive Manual (7Th Edition). Elsevier India. pp. 122–. ISBN 978-81-312-1150-2. https://books.google.com/books?id=pzanxKlcU74C&pg=PA122. 
  72. "Comparative pharmacology of newer progestogens". Drugs 51 (2): 188–215. 1996. doi:10.2165/00003495-199651020-00002. PMID 8808163.  https://dx.doi.org/10.2165%2F00003495-199651020-00002
  73. Stefan Offermanns; Walter Rosenthal (14 August 2008). Encyclopedia of Molecular Pharmacology. Springer Science & Business Media. pp. 391–. ISBN 978-3-540-38916-3. https://books.google.com/books?id=iwwo5gx8aX8C&pg=PA391. 
  74. Lara Marks (2001). Sexual Chemistry: A History of the Contraceptive Pill. Yale University Press. pp. 73–75, 77–78. ISBN 978-0-300-08943-1. https://books.google.com/books?id=GgvLA3bqwnoC&pg=PA77. 
  75. "The use of norethynodrel (enovid) in clinical practice". Can Med Assoc J 84: 584–7. 1961. PMID 13753182. "Pseudohermaphroditism should not be a problem in these patients as it appears that norethynodrel does not possess androgenic properties, but it is believed that Wilkins has now found one such case in a patient who has been on norethynodrel therapy.".  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1939348
  76. "Receptor profiling and endocrine interactions of tibolone". Steroids 68 (1): 21–30. 2003. doi:10.1016/s0039-128x(02)00112-5. PMID 12475720.  https://dx.doi.org/10.1016%2Fs0039-128x%2802%2900112-5
  77. Ruggieri, Pietro de; Matscher, Rodolfo; Lupo, Corrado; Spazzoli, Giacomo (1965). "Biological properties of 17α-vinyl-5(10)-estrene-17β-ol-3-one (norvinodrel) as a progestational and claudogenic compound". Steroids 5 (1): 73–91. doi:10.1016/0039-128X(65)90133-9. ISSN 0039-128X.  https://dx.doi.org/10.1016%2F0039-128X%2865%2990133-9
  78. J. A. Simpson; E. S. C. Weiner (1997). Oxford English Dictionary Additions Series. Clarendon Press. pp. 36–. ISBN 978-0-19-860027-5. https://books.google.com/books?id=gUGcAQAAQBAJ&pg=PA36. 
  79. JUCKER (8 March 2013). Fortschritte der Arzneimittelforschung / Progress in Drug Research / Progrès des recherches pharmaceutiques. Birkhäuser. pp. 166–. ISBN 978-3-0348-7053-5. https://books.google.com/books?id=BH4ECAAAQBAJ&pg=PA166. 
  80. Annual Reports in Medicinal Chemistry. Academic Press. 8 September 1989. pp. 199–. ISBN 978-0-08-058368-6. https://books.google.com/books?id=HrALiG-4t7UC&pg=PA199. 
  81. "Progestogens with antiandrogenic properties". Drugs 63 (5): 463–92. 2003. doi:10.2165/00003495-200363050-00003. PMID 12600226. http://content.wkhealth.com/linkback/openurl?issn=0012-6667&volume=63&issue=5&spage=463. 
  82. "Androgens and antiandrogens". Annals of the New York Academy of Sciences 997: 292–306. 2003. doi:10.1196/annals.1290.033. PMID 14644837. Bibcode: 2003NYASA.997..292S.  https://dx.doi.org/10.1196%2Fannals.1290.033
  83. Botella, J.; Paris, J.; Lahlou, B. (1987). "The cellular mechanism of the antiandrogenic action of nomegestrol acetate, a new 19-nor progestagen, on the rat prostate". European Journal of Endocrinology 115 (4): 544–550. doi:10.1530/acta.0.1150544. ISSN 0804-4643.  https://dx.doi.org/10.1530%2Facta.0.1150544
  84. "Metabolic and clinical effects of progestogens". Eur J Contracept Reprod Health Care 11 (3): 153–61. 2006. doi:10.1080/13625180600772741. PMID 17056444.  https://dx.doi.org/10.1080%2F13625180600772741
  85. "Prodrugs: advantage or disadvantage?". Am. J. Obstet. Gynecol. 163 (6 Pt 2): 2198–203. 1990. PMID 2256526.  http://www.ncbi.nlm.nih.gov/pubmed/2256526
  86. "Inherent estrogenicity of norethindrone and norethynodrel: comparison with other synthetic progestins and progesterone". J. Clin. Endocrinol. Metab. 22: 1033–9. 1962. doi:10.1210/jcem-22-10-1033. PMID 13942007.  https://dx.doi.org/10.1210%2Fjcem-22-10-1033
  87. Neumann, F.; Duesterberg, B.; Laurent, H. (1988). "Development of Progestogens". Female Contraception: 129–140. doi:10.1007/978-3-642-73790-9_11.  https://dx.doi.org/10.1007%2F978-3-642-73790-9_11
  88. Philip W. Harvey (28 March 1996). Adrenal in Toxicology: Target Organ and Modulator of Toxicity. CRC Press. pp. 284–. ISBN 978-0-7484-0330-1. https://books.google.com/books?id=ifDqvypO4ikC&pg=PA284. 
  89. Alfred Cuschieri; George Hanna (20 January 2015). Essential Surgical Practice: Higher Surgical Training in General Surgery, Fifth Edition. CRC Press. pp. 899–. ISBN 978-1-4441-3763-7. https://books.google.com/books?id=m2EDCwAAQBAJ&pg=PA899. 
  90. John A. Thomas (12 March 1997). Endocrine Toxicology, Second Edition. CRC Press. pp. 152–. ISBN 978-1-4398-1048-4. https://books.google.com/books?id=URc5JMoNirgC&pg=PA152. 
  91. Nick Panay; Paula Briggs; Gab Kovacs (20 August 2015). Managing the Menopause. Cambridge University Press. pp. 126–. ISBN 978-1-107-45182-7. https://books.google.com/books?id=l0pLCgAAQBAJ&pg=PA126. 
  92. Meis, Paul J. (2005). "17 Hydroxyprogesterone for the Prevention of Preterm Delivery". Obstetrics & Gynecology 105 (5, Part 1): 1128–1135. doi:10.1097/01.AOG.0000160432.95395.8f. ISSN 0029-7844. PMID 15863556.  https://dx.doi.org/10.1097%2F01.AOG.0000160432.95395.8f
  93. "Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone". Eur J Contracept Reprod Health Care 7 Suppl 3: 19–26; discussion 42–3. 2002. PMID 12659403.  http://www.ncbi.nlm.nih.gov/pubmed/12659403
  94. "Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen". Gynecol. Endocrinol. 23 (12): 692–9. 2007. doi:10.1080/09513590701582323. PMID 18075844.  https://dx.doi.org/10.1080%2F09513590701582323
  95. "Drospirenone and its antialdosterone properties". Climacteric 10 Suppl 1: 11–8. 2007. doi:10.1080/13697130601114891. PMID 17364593.  https://dx.doi.org/10.1080%2F13697130601114891
  96. "Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism". Maturitas 55 (4): 297–307. 2006. doi:10.1016/j.maturitas.2006.07.009. PMID 16949774.  https://dx.doi.org/10.1016%2Fj.maturitas.2006.07.009
  97. "The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface". Mol. Pharmacol. 55 (2): 269–78. February 1999. PMID 9927618. http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=9927618. 
  98. "Untersuchungen in der Sexualhormon-Reihe (Investigations in the sex hormone series)". Ber Dtsch Chem Ges 71 (5): 1024–32. May 4, 1938. doi:10.1002/cber.19380710520. http://www3.interscience.wiley.com/cgi-bin/abstract/112367144/ABSTRACT. 
  99. Maisel, Albert Q. (1965). The Hormone Quest. New York: Random House. OCLC 543168.  http://www.worldcat.org/oclc/543168
  100. Petrow V (1970). "The contraceptive progestagens". Chem Rev 70 (6): 713–26. doi:10.1021/cr60268a004. PMID 4098492.  https://dx.doi.org/10.1021%2Fcr60268a004
  101. Sneader, Walter (2005). "Hormone analogues". Drug discovery : a history. Hoboken, NJ: John Wiley & Sons. pp. 188–225. ISBN 0-471-89980-1. 
  102. Djerassi C (2006). "Chemical birth of the pill". Am J Obstet Gynecol 194 (1): 290–8. doi:10.1016/j.ajog.2005.06.010. PMID 16389046.  https://dx.doi.org/10.1016%2Fj.ajog.2005.06.010
  103. "Steroids. LIV. Synthesis of 19-Nor-17α-ethynyltestosterone and 19-Nor-17α-methyltestosterone" (PDF). J Am Chem Soc 76 (16): 4089–91. 1954. doi:10.1021/ja01645a009. http://pubs.acs.org/cgi-bin/abstract.cgi/jacsat/1954/76/i16/f-pdf/f_ja01645a010.pdf. 
  104. Colton FB (1992). "Steroids and "the pill": early steroid research at Searle". Steroids 57 (12): 624–30. doi:10.1016/0039-128X(92)90015-2. PMID 1481226.  https://dx.doi.org/10.1016%2F0039-128X%2892%2990015-2
  105. John David Gordon; Jan Rydfors; Maurice Druzin; Yasser El-Sayed; Yona Tadir (2007). Obstetrics, Gynecology & Infertility: Handbook for Clinicians. Scrub Hill Press, Inc.. pp. 229–. ISBN 978-0-9645467-7-6. https://books.google.com/books?id=2JLC6yiA7fcC&pg=PA229. 
  106. Ronald S. Gibbs (2008). Danforth's Obstetrics and Gynecology. Lippincott Williams & Wilkins. pp. 568–. ISBN 978-0-7817-6937-2. https://books.google.com/books?id=v4krPhqFG8sC&pg=PA568. 
  107. C. Coutifaris; L. Mastroianni (15 August 1997). New Horizons in Reproductive Medicine. CRC Press. pp. 101–. ISBN 978-1-85070-793-6. https://books.google.com/books?id=dmokq_M-gm8C&pg=PA101. 
  108. Shio Kumar Singh (4 September 2015). Mammalian Endocrinology and Male Reproductive Biology. CRC Press. pp. 270–. ISBN 978-1-4987-2736-5. https://books.google.com/books?id=Y-KYCgAAQBAJ&pg=PA270. 
  109. Frick, J. (1973). "Control of spermatogenesis in men by combined administration of progestin and androgen". Contraception 8 (3): 191–206. doi:10.1016/0010-7824(73)90030-9. ISSN 00107824.  https://dx.doi.org/10.1016%2F0010-7824%2873%2990030-9
  110. "7α-methyl-19-nortestosterone (MENTR): the population council's contribution to research on male contraception and treatment of hypogonadism". Contraception 87 (3): 288–95. 2013. doi:10.1016/j.contraception.2012.08.036. PMID 23063338.  https://dx.doi.org/10.1016%2Fj.contraception.2012.08.036
  111. "Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity". Endocrinology 147 (6): 3016–26. 2006. doi:10.1210/en.2005-1524. PMID 16497801.  https://dx.doi.org/10.1210%2Fen.2005-1524
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Others
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
HandWiki
View Times: 2.1K
Entry Collection: HandWiki
Revision: 1 time (View History)
Update Date: 21 Oct 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Write an Entry
    Feedback